Merck & Co., Inc.
NYSE:MRKDrug Manufacturers - General
-$1.32 today
- Market cap
- $339.66B
- Beta
- 0.22
- P/E (TTM)
- 31.6
- EPS (TTM)
- $3.61
- Dividend yield
- 2.94%
Volume 9.69M
Average 11.85M
MRK Debt Repayment
Cash used to repay borrowings during the period.
Merck & Co., Inc.NYSE: MRK
Debt Repayment · Q2 FY2026 · quarter ended Jun 2026
Debt repayment growth accelerates
Q2 FY2026 debt repayment of $4.89B rose 10087.5% year over year, ahead of the +723.0% change in trailing-twelve-month debt repayment.
Context
- Debt repayment amounted to 17.5% of revenue in FY2025, up 13.9 pp from a year earlier.
- Debt repayment increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +10087.5% holds above the trailing-twelve-month pace of +723.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
USD · from the cash flow
- Latest · FY2025
- 11.38B USD
- Year-over-year change
- +392.7%
- 4-year CAGR
- +62.5%
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.38B | +392.7% |
| FY2024 | 2024-12-31 | 2.31B | -44.8% |
| FY2023 | 2023-12-31 | 4.18B | +285.9% |
| FY2022 | 2022-12-31 | (2.25B) | -238.0% |
| FY2021 | 2021-12-31 | 1.63B | — |
Debt Repayment vs competitors
How MRK compares with its peers on the latest reported figures
- Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +723.0% is the highest of 9, against a peer median of +84.4%.
- Debt repayment amounts to 28.1% of revenue for MRK, versus a peer median of 3.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $18.64B USD | +723.0% | — | 28.1% | |
| LTM Jun 2026 | $16.59B USD | +704.5% | — | 29.8% | |
| LTM Jun 2026 | $15.22B USD | +47.0% | — | 19.1% | |
| LTM Jun 2026 | €3.21B EUR | — | — | 6.6% | |
| LTM Jun 2026 | $1.78B USD | +121.9% | -72.4% | 2.8% | |
| LTM Jun 2026 | $1.32B USD | +157.5% | — | 3.5% | |
| LTM Jun 2026 | $1.29B USD | -18.4% | +6.0% | 4.2% | |
| LTM Sep 2026 | $793.27M USD | +8.5% | +11.3% | 1.3% | |
| LTM Sep 2026 | $787M USD | -108.7% | +8.9% | 0.8% | |
| LTM Jun 2026 | $418M USD | +130.0% | -70.3% | 0.6% | |
| Peer median (excluding MRK) | — | +84.4% | +6.0% | 3.5% | |
Competitors are the stored peer set for MRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 12.36B | 14.53B | 365M | 17.13B | 18.25B |
| Depreciation & Amortization | 3.21B | 3.91B | 3.87B | 4.5B | 5.84B |
| Deferred Income Tax | 187M | (1.57B) | (1.9B) | (1.25B) | (1.67B) |
| Stock-Based Compensation | 479M | 541M | 645M | 761M | 0 |
| Change in Working Capital | (3.84B) | (2.78B) | (2.21B) | (3.67B) | (6.98B) |
| Accounts Receivables | (2.03B) | (644M) | (1.15B) | (244M) | (1.09B) |
| Inventory | (674M) | (161M) | (816M) | (835M) | (1.18B) |
| Accounts Payables | 405M | (289M) | (380M) | 182M | 110M |
| Other Working Capital | (1.54B) | (1.69B) | 139M | (2.77B) | (4.82B) |
| Other Non-Cash Items | 1.71B | 4.47B | 12.23B | 3.99B | 1.03B |
| Operating Cash Flow | 14.11B | 19.1B | 13.01B | 21.47B | 16.47B |
| Capital Expenditures | (4.45B) | (4.39B) | (3.86B) | (3.37B) | (4.11B) |
| Acquisitions (Net) | (12.91B) | (121M) | (12.03B) | (4.09B) | (10.04B) |
| Purchases of Investments | (1M) | (1.2B) | (955M) | (519M) | (1.21B) |
| Sales of Investments | 1.03B | 721M | 1.66B | 377M | 1.68B |
| Other Investing Activities | (225M) | 32M | 1.11B | (127M) | (58M) |
| Investing Cash Flow | (16.56B) | (4.96B) | (14.08B) | (7.73B) | (13.74B) |
| Debt Repayment | 1.63B | (2.25B) | 4.18B | 2.31B | 11.38B |
| Common Stock Issued | 0 | 384M | 0 | 0 | 92M |
| Common Stock Repurchased | (840M) | 0 | (1.35B) | (1.31B) | (5.08B) |
| Dividends Paid | (6.61B) | (7.01B) | (7.45B) | (7.84B) | (8.18B) |
| Other Financing Activities | 8.41B | (240M) | (203M) | (195M) | (131M) |
| Financing Cash Flow | 2.59B | (9.12B) | (4.81B) | (7.03B) | (1.92B) |
| Effect of Forex Changes | (133M) | (410M) | 23M | (293M) | 563M |
| Net Change in Cash | 14M | 4.61B | (5.86B) | 6.41B | 1.37B |
| Free Cash Flow | 9.66B | 14.71B | 9.14B | 18.1B | 12.36B |
Merck & Co., Inc.
NYSE:MRK
Intrinsic Alpha fair value
Locked
Current Price
$137.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.